324 related articles for article (PubMed ID: 36040792)
41. Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms.
Chao MM; Thomay K; Goehring G; Wlodarski M; Pastor V; Schlegelberger B; Schindler D; Kratz CP; Niemeyer C
Klin Padiatr; 2017 Nov; 229(6):329-334. PubMed ID: 29132164
[TBL] [Abstract][Full Text] [Related]
42. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
Figg JW; Barajas JM; Obeng EA
Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
[TBL] [Abstract][Full Text] [Related]
44. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
[TBL] [Abstract][Full Text] [Related]
45. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
46. [Splicing factor mutations in myelodysplastic syndromes].
Shiozawa Y
Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
49. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
[TBL] [Abstract][Full Text] [Related]
50. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.
Mian SA; Rouault-Pierre K; Smith AE; Seidl T; Pizzitola I; Kizilors A; Kulasekararaj AG; Bonnet D; Mufti GJ
Nat Commun; 2015 Dec; 6():10004. PubMed ID: 26643973
[TBL] [Abstract][Full Text] [Related]
51. Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.
Asimomitis G; Deslauriers AG; Kotini AG; Bernard E; Esposito D; Olszewska M; Spyrou N; Arango Ossa J; Mortera-Blanco T; Koche R; Nannya Y; Malcovati L; Ogawa S; Cazzola M; Aaronson SA; Hellström-Lindberg E; Papaemmanuil E; Papapetrou EP
Blood Adv; 2022 May; 6(10):2992-3005. PubMed ID: 35042235
[TBL] [Abstract][Full Text] [Related]
52. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
53. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
54. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
55. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
[TBL] [Abstract][Full Text] [Related]
56. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
57. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
58. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
59. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
60. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.
Benbarche S; Pineda JMB; Galvis LB; Biswas J; Liu B; Wang E; Zhang Q; Hogg SJ; Lyttle K; Dahi A; Lewis AM; Sarchi M; Rahman J; Fox N; Ai Y; Mehta S; Garippa R; Ortiz-Pacheco J; Li Z; Monetti M; Stanley RF; Doulatov S; Bradley RK; Abdel-Wahab O
Mol Cell; 2024 May; 84(10):1886-1903.e10. PubMed ID: 38688280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
